{"id":47883,"date":"2022-09-01T11:02:08","date_gmt":"2022-09-01T09:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/insights-on-the-nasal-drug-delivery-mode-global-market-to-2028-size-share-outlook-and-opportunity-analysis-researchandmarkets-com\/"},"modified":"2022-09-01T11:02:08","modified_gmt":"2022-09-01T09:02:08","slug":"insights-on-the-nasal-drug-delivery-mode-global-market-to-2028-size-share-outlook-and-opportunity-analysis-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/insights-on-the-nasal-drug-delivery-mode-global-market-to-2028-size-share-outlook-and-opportunity-analysis-researchandmarkets-com\/","title":{"rendered":"Insights on the Nasal Drug Delivery Mode Global Market to 2028 – Size, Share, Outlook and Opportunity Analysis – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Nasal Drug Delivery Mode Market, by Therapeutic Application, by Dosage Form, by Container Type, by System Type, by End-users, by Distribution, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nDrug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption. Intranasal drug delivery offers a rapid onset of therapeutic effects (local or systemic). Nasal applications of topical decongestants or anti-inflammatory drugs are most popular topical nasal drug deliveries.\n<\/p>\n

\nNasal delivery is the logical choice for treatment of diseases in the nose and paranasal sinuses. Over the years, nasal route has gained widespread interest as a promising and an alternative route to oral and parenteral drug delivery.\n<\/p>\n

\nGrowing prevalence of asthma and chronic obstructive pulmonary disease (COPD), increasing adoption of self-administration practices, and increasing preference for nasal drug delivery are some major factors expected to boost the growth of the global nasal drug delivery mode market over the forecast period. Asthma is a major noncommunicable disease (NCD) that affects both children and adults.\n<\/p>\n

\nFor instance, according to the Asthma and Allergy Foundation of America (AAFA), more than 25 million people in the U.S. have asthma, about 1 in 13 people. Moreover, over 20 million adults aged 18 and older have asthma in the U.S., and asthma rates are highest in Black adults in the United States.\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n